Zogenix, Inc.   Report issue

Founded: San Diego CA United States (2006)
Status: Acquired by UCB (2022)

Organization Overview

First Clinical Trial
2006
NCT02117141
First Marketed Drug
2020
fenfluramine (Pondimin)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Zogenix, Inc. | ZOGENIX INC | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.